As per our report, the Global BBB Technologies Market will grow at a remarkable CAGR of 22% from 2021 to 2026. Advances in biotechnology have enabled the development of versatile in-vitro, in-vivo, in-situ blood-brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries.
The blood-brain barrier plays a vital role in protecting the brain from blood-borne diseases and toxic compounds as they help people suffering from neural diseases like brain cancer Alzheimer's. Alzheimer's requires the development of new drugs such as recombinant protein or gene therapies; there is an excellent scope for the development of new drugs for the brain as there was no new approval for new recombinant drug by the FDA. Thus, low-weight molecule drugs and biomacromolecules such as DNA and protein are used to treat neurological diseases. There are many types of research on developing new techniques for entry of the drug in the brain without damaging the blood-brain barrier membrane.
Epilepsy, sclerosis, obesity, Alzheimer's, Parkinson, neurotransmitters are neurologic are few of the areas to which several patents on the BBB technologies being exploited for designing drugs against widespread CND disorders. Over the years, more than 16700 licenses related to BBB technologies have been granted to various industry and non-industry players, indicating R & D's pace in this burgeoning field of research. Around 62% of patents related to BBB technologies have been granted in the United States; the Asia Pacific followed this with more than 2300 patents.
The brain is one of the most extensive and most intricate organs in the human body. It consists of 100 billion nerves that communicate with 100 trillion synapses. It is up of midbrain, hindbrain, and forebrain. It is responsible for movement and thought produced by the body. It has its security system- a filtering mechanism consisting of blood vessels that allow entry of essential nutrients and block other substances known as the blood-brain barrier. The blood-brain barrier is a semi-permeable dynamic interface that separates the capillaries that carry blood to the brain and spinal cord tissue by blocking certain substances' passage. The blood-brain barrier vessels are up of specialized endothelial cells, which lines brain capillaries from the vascular system, which lack the fenestration of pores and allow rapid exchange of molecules between vessels and tissues. The blood-brain barrier protects the neural tissue from harmful chemicals and maintains a stable environment.
However, this barrier is so effective at blocking the entry of foreign substances that it often prevents penetration of life-saving drugs to address issues like injuries and diseases. Therefore, the discovery of new methods allowing the effective delivery of medicines and bio-macromolecules to the central nervous system (CNS) is of immense importance for the treatment of neurodegenerative disorders.
The growing burden related to CNS is the significant growth driving force to the global blood-brain technologies market.
Effective drug delivery across the blood-brain barrier is one of the most impediments to the successful treatment of CNS related diseases and brain tumors. Around 1.5 billion people are affected by CND related infections globally. The global CNS drug market has a market worth of more than 125 billion USD. More than 100 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS treatments; there are 25+ technology platforms for developing BBB penetrant drugs.
The public and private organizations are increasing the funds for the research of the blood-brain barrier technology, propelling market growth. The research team from the Kumamoto University Japan is working on developing a cyclic peptide. There is research on creating a variety of invasive and non-invasive techniques to deliver drugs through the blood-brain barrier without disrupting the membrane. The monoclonal antibody can penetrate through the blood-brain barrier.
Additionally, the growing prevalence of neurological diseases like Parkinson's disease, meningitis, multiple sclerosis, and encephalitis, augmenting the geriatric population, and rising healthcare expenditure further accelerate market growth. Furthermore, increasing investment in R&D for the development of new drugs and delivery devices, growing awareness about healthcare, and an increasing number of initiatives by various governments and affiliated associations are projected to fuel the blood-brain barrier technologies market.
On the other hand, intricate regulatory frameworks for the approval of drugs in most countries and inordinate approval time for medications due to the insufficient knowledge of the brain are primary restraints for the growth of the market. People in rural areas are less aware of the latest technologies, which is slowly inhibiting market demand. Lack of proper knowledge in the procedure due to less training programs by the government hinders the market's growth rate.
Market Size Available
2021 to 2026
2021 to 2026
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
North America leads the global market, given the increasing incidence of neurological diseases and augmenting the geriatric population.
Asia shows high growth rates in the forecast period in the market, with China and India being the fastest-growing markets in the Asia Pacific. The primary driving forces for the market in emerging economies are the large pool of patients, growing awareness about the disease, improving healthcare infrastructure, and increasing government funding in the region.
KEY MARKET PARTICIPANTS:
Some of the promising companies operating in the Global Blood-Brain Barrier Technologies Market are Bristol-Myers Squibb Company, Pfizer, Inc., biOasia Technologies, Inc., Cypress Biosciences, Inc., Janssen Pharmaceutical N.V., Teva Pharmaceuticals Industries, Ltd., F. Hoffmann La-Roche, Ltd., Eli Lilly and Company, Fabre-Kramer Pharmaceuticals, Inc., NeuroVive Pharmaceutical AB, and ArmaGen.
Several technology developers are presently focusing on integrating advanced technical features into their proprietary drug development or delivery platforms to achieve a competitive edge. An assessment of 240+ drug developers focused on Parkinson's and Alzheimer's diseases, revealed that many firms are likely to partner with technology providers to leverage their BBB penetration expertise.
RECENT MARKET DEVELOPMENTS:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 North America
5.1.3 Latin America
5.1.5 Asia Pacific
5.1.6 Middle East and Africa
5.1.7 Y-o-Y Growth Analysis, By Geography
5.1.8 Market Attractiveness Analysis, By Geography
5.1.9 Market Share Analysis, By Geography
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
18.104.22.168 By Geographical Area
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Allon Therapeutics, Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AngioChem Inc.
8.4 CeNeRx BioPharma, Inc
8.5 Bioasis Technologies Inc.
8.6 Ablynx NV
8.7 Capsulution Pharma AG
8.8 International Brain Barriers Society (IBBS)
8.9 Cephalon Inc
8.10 Cognition Pharmaceuticals LLC
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures